---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-24-000140"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T14:56:04.588028+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MacroGenics receives $100M milestone payment from Incyte for retifanlimab collaboration

## Summary
- MacroGenics and Incyte amended their 2017 collaboration agreement, deeming milestones achieved and triggering a $100M payment to MacroGenics.
- MacroGenics confirms cash runway guidance into 2026, supported by the $100M milestone plus expected partner payments and product revenues.
- Total milestones achieved from Incyte now reach $215M since the initial 2017 collaboration.
- Retifanlimab (ZYNYZ) is a PD-1 inhibitor for Merkel cell carcinoma, originally developed by MacroGenics and licensed to Incyte.
- MacroGenics remains eligible for up to $210M in development/regulatory milestones and $330M in commercial milestones from Incyte.

## SEC filing metadata
- accession: 0001125345-24-000140
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000140/0001125345-24-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000140/mgnx-20240724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-24-000140
- JSON: https://secwatch.observer/filing/0001125345-24-000140.json
- Plain text: https://secwatch.observer/filing/0001125345-24-000140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.